Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sun Pharmaceuticals Industries's Net Margin % or its related term are showing as below:
BOM:524715'
s Net Margin % Range Over the Past 10 Years
Min: 8.04 Med: 15.62 Max: 23.22
Current: 19.72
BOM:524715's Net Margin % is ranked better than 86.78% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.54
vs BOM:524715: 19.72
Sun Pharmaceuticals Industries (BOM:524715) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sun Pharmaceuticals Industries Net Margin % Related Terms
Sun Pharmaceuticals Industries Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries (BOM:524715) has a Net Margin % of 18.64% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sun Pharmaceuticals Industries and its competitors. This is 19% above median its historical median of 15.62. Over the past decade, Sun Pharmaceuticals Industries' Net Margin % has ranged from 8.04 to 23.22. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #127 out of 961 companies in the Drug Manufacturers industry, placing it in the top 13.2%.
Is Sun Pharmaceuticals Industries' Net Margin % too high?
Sun Pharmaceuticals Industries' current Net Margin % of 18.64% is 19% above median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 8.04 to a high of 23.22. The Drug Manufacturers industry median Net Margin % is 5.54. Sun Pharmaceuticals Industries' value of 18.64% is 236.5% above this industry median. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #127 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #127 out of 961 companies for Net Margin %. This places Sun Pharmaceuticals Industries in the top 13% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.54. Sun Pharmaceuticals Industries' value of 18.64% is 236.5% above this benchmark. Historically, Sun Pharmaceuticals Industries' own Net Margin % has ranged from 8.04 to 23.22 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 5.54, Sun Pharmaceuticals Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.54, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharmaceuticals Industries's current Net Margin % of 18.64% is 236.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sun Pharmaceuticals Industries and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharmaceuticals Industries's current Net Margin % is 18.64%, which is 19% above median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (BOM:524715) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,927.98, compared to a current price of ₹1,973.50 — trading 2.4% above its estimated fair value. The current Net Margin % is 18.64%, which is 19% above median its 10-year median of 15.62 and 236.5% above the Drug Manufacturers industry median of 5.54. Sun Pharmaceuticals Industries' overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (BOM:524715), the current Net Margin % is 18.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (BOM:524715) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be overvalued.
The current stock price of ₹1,973.50 is trading 2.4% above its estimated GF Value™ of ₹1,927.98.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for BOM:524715:
Net Margin %: 18.64% (19% above median its 10-year median of 15.62)
GF Value™: ₹1,927.98 vs. price of ₹1,973.50 (2.4% above fair value)
Industry Position: 236.5% above the Drug Manufacturers median (#127 of 961)
No single metric tells the full story. See the BOM:524715 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Business Description
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
91GF Score
Get the complete analysis for BOM:524715
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524715 has been successfully added to your 
